InhibRx Competitors and Similar CompaniesClear all
InhibRx's competitors and similar companies include Arvelle Therapeutics, Secura Bio and Keros Therapeutics.
 InhibRx InhibRx is a clinical-stage biotechnology company developing a broad pipeline of novel biologic therapeutic candidates. |  Secura Bio Secura Bio is an integrated biopharmaceutical company dedicated to the commercialization of oncology therapies. |  Keros Therapeutics Keros Therapeutics is a biotechnology company that develops therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta. | ||
Founding Date | Founding Date 2017 | Founding Date 2019 | Founding Date 2019 | Founding Date 2015 |
Type | Type Public | Type Subsidiary | Type Private | Type Public |
Tags | ||||
Locations | Locations San Diego, US HQ | Locations Zug, CH HQ Zug, CH | Locations Las Vegas, US HQ San Diego, US | Locations Lexington, US HQ South Wharf, AU |
Employees | Employees 1531% increase | Employees 10 | Employees 489% increase | Employees 7854% decrease |
Valuation ($) | Valuation ($) 233.1 m | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 2.3 b |
Financial | ||||
Revenue (est.) | Revenue (est.) $1.8m (FY, 2023) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $244.1m (FY, 2025) |
Net income | Net income ($241.4m) (FY, 2023) | Net income N/A | Net income N/A | Net income $87m (FY, 2025) |
Funding | ||||
Total funding raised | Total funding raised $ 43.6m | Total funding raised $ 180m | Total funding raised $ 195m | Total funding raised $ 90m |
For sources of this data, please see the company profile
View Company Profiles
Secura Bio
HQ
Las Vegas, US
Employees
48↑ 9% increase
Secura Bio is an integrated biopharmaceutical company dedicated to the commercialization of oncology therapies.
View companyKeros Therapeutics
HQ
Lexington, US
Employees
78
Keros Therapeutics is a biotechnology company that develops therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta.
View company